ES2536235T3 - Dispositivo polimérico de liberación prolongada - Google Patents
Dispositivo polimérico de liberación prolongada Download PDFInfo
- Publication number
- ES2536235T3 ES2536235T3 ES11180259.1T ES11180259T ES2536235T3 ES 2536235 T3 ES2536235 T3 ES 2536235T3 ES 11180259 T ES11180259 T ES 11180259T ES 2536235 T3 ES2536235 T3 ES 2536235T3
- Authority
- ES
- Spain
- Prior art keywords
- sucrose
- composition
- oil
- mecl2
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000013265 extended release Methods 0.000 title 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 27
- 239000000203 mixture Substances 0.000 abstract description 21
- 229930006000 Sucrose Natural products 0.000 abstract description 20
- 239000005720 sucrose Substances 0.000 abstract description 20
- 239000011148 porous material Substances 0.000 abstract description 12
- 108010011459 Exenatide Proteins 0.000 abstract description 5
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract description 5
- 229960001519 exenatide Drugs 0.000 abstract description 5
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052753 mercury Inorganic materials 0.000 abstract description 3
- 230000001687 destabilization Effects 0.000 abstract description 2
- 238000002459 porosimetry Methods 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 229920000249 biocompatible polymer Polymers 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- 238000009472 formulation Methods 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 8
- 239000011859 microparticle Substances 0.000 description 7
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 229920002545 silicone oil Polymers 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 2
- 0 CC(C)C(C)C(C)(*1)C(*IC)C1[C@]1C2(C)[C@](C)CS*12 Chemical compound CC(C)C(C)C(C)(*1)C(*IC)C1[C@]1C2(C)[C@](C)CS*12 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Una composición para la liberación prolongada de un polipéptido biológicamente activo, que comprende un polímero biocompatible que tiene el polipéptido biológicamente activo dispersado en él de modo que esté presente de un 3% (p/p) a un 10% (p/p) del peso de la composición y sacarosa dispersada en él de modo que esté presente en un 2% (p/p) del peso de la composición, donde el polipéptido biológicamente activo es exendina-4, donde el volumen de poro total de la composición es de 0.1 mL/g o menos según se determina utilizando porosimetría por intrusión de mercurio y donde la composición está exenta de tampones y de sales de desestabilización salina.
Description
E11180259
04-05-2015
donde:
D = diámetro del poro γ = tensión superficial (constante) θ = ángulo de contacto (constante)
5 P = presión
Por lo tanto, el tamaño del poro en el cual se introducirá el mercurio es inversamente proporcional a la presión aplicada. Asumiendo que todos los poros son cilindros rígidos, el diámetro del poro promedio (D=4V/A) se puede calcular dividiendo el volumen del poro (V=πD2h/4) por el área del poro (A=πDh).
DISOLVENTES RESIDUALES
10 Se utilizó un único método para la cuantificación de heptano, etanol y diclorometano. El equipo estuvo constituido por un cromatógrafo de gases HP 5890 Serie 2 con una columna Rtx 1301, 30 cm x 0.53 mm. Se disolvieron aproximadamente 130 mg de micropartículas en 10 mL de N,N-dimetilformamida. Se utilizó acetato de propilo como patrón interno. Se ajustó la preparación de la muestra de modo que se pudieran cuantificar concentraciones de diclorometano de tan solo un 0.03%.
Se prepararon los lotes de micropartículas expuestos en la Tabla 1 según se ha descrito anteriormente a una escala de 100 gramos utilizando el polímero 4A y una relación de aceite de silicona respecto al diclorometano de 1.5:1 o de
1:1 y el aceite de silicona tuvo una viscosidad de 350 cs. La cantidad de exendina-4 y los excipientes utilizados en la formulación también se exponen en la Tabla 1.
20 TABLA 1
- Lote n.º
- Formulación Liberación brusca in vitro (%) Observaciones
- 02-019-147(n.º 1)
- 0% de sacarosa, 0% de SA 0.40 1.5:1 Aceite de Si: MeCl2
- 02-019-167(n.º 2)
- 2% de sacarosa (F16) 0.40 1.5:1 Aceite de Si: MeCl2
- 02-019-160(n.º 2.1)
- 2% de sacarosa (F16) 0.44 1.5:1 Aceite de Si l: MeCl2
- 02-019-164(n.º 2-2)
- 2% de sacarosa (F16) 0.45 1.5:1 Aceite de Si: MeCl2
- 02-030-08(n.º 2-3)
- 2% de sacarosa (F16) 0.80 1:1 Aceite de Si: MeCl2
- 02-030-01(n.º 2-4)
- 2% de sacarosa (F16) 1.0 1:1 Aceite de Si: MeCl2
- 02-030-04(n.º 2-5)
- 2% de sacarosa (F16) 1.1 1:1 Aceite de Si: MeCl2
- 02-019-136(n.º 3-1)
- 2% de sacarosa, 0.5% de SA (F14) 1.3 50:50 Desactivación
- 02-019-115(n.º 3-2)
- 2% de sacarosa, 0.5% de SA (F14) 2.2 1.5:1 Aceite de Si: MeCl2
- 02-019-170(n.º 4)
- 0% de sacarosa, 0.5% de SA 3.8 1.5:1 Aceite de Si: MeCl2
- 02-019-133A(n.º 3-3)
- 2% de sacarosa, 0.5% de SA (F14) 12.7 100% Desactivación con heptano
- 02-019-185(n.º 5) (5% de adición del fármaco)
- 2% de sacarosa (F17) 0.5 5% de adición del fármaco, 1.5:1 Aceite de Si: MeCl2
- 02-019-64 (n.º 3-4)
- 2% de sacarosa, 0.5% de SA (F14) 0.5 1.5:1 Aceite de Si: MeCl2
- 02-019-10(n.º 3-5)
- 2% de sacarosa, 0.5% de SA (F14) 1.30 1:1 Aceite de Si: MeCl2
- 02-001-196(n.º 3-6)
- 2% de sacarosa, 0.5% de SA (F14) 2.70 1:1 Aceite de Si: MeCl2
- 02-019-24(n.º 3-7)
- 2% de sacarosa, 0.5% de SA (F14) 6.70 1:1 Aceite de Si: MeCl2
- *TODAS LAS FORMULACIONES TUVIERON UNA ADICIÓN DEL FÁRMACO DE UN 3% CON LA EXCEPCIÓN
12
E11180259
04-05-2015
- Lote n.º
- Formulación Liberación brusca in vitro (%) Observaciones
- DE LA POROSIDAD N.º 5
El volumen de intrusión total obtenido de la porosimetría por intrusión de mercurio y los diámetros de poro promedio calculados se proporcionan en la TABLA 2. La relación entre el diámetro de poro promedio y la liberación in vitro se muestra en la FIG. 1.
TABLA 2
- Lot n.º
- Volumen del Poro Total (mL/g) Liberación brusca in vitro (%) Diámetro del poro promedio (µm)
- 02-019-147(n.º 1)
- 0.033 0.40 0.0068
- 02-019-167(n.º 2)
- 0.035 0.40 0.0069
- 02-019-160(n.º 2-1)
- 0.037 0.44 0.0070
- 02-019-164(n.º 2-2)
- 0.035 0.45 0.0070
- 02-030-08(n.º 2-3)
- 0.036 0.80 0.0070
- 02-030-01 (n.º 2-4)
- 0.038 1.0 0.0073
- 02-030-04(n.º 2-5)
- 0.039 1.1 0.0074
- 02-019-136(n.º 3-1)
- 0.041 1.3 0.0073
- 02-019-115(n.º 3-2)
- 0.039 2.2 0.0078
- 02-019-170(n.º 4)
- 0.067 3.8 0.0125
- 02-019-133A(n.º 33)
- 0.513 12.7 0.0277
- 02-019-64 (n.º 3-4)
- 0.030 0.5 0.0060
- 02-019-10(n.º 3-5)
- 0.060 1.30 0.0090
- 02-001-196(n.º 3-6)
- 0.060 2.70 0.0100
- 02-019-24(n.º 3-7)
- 0.180 6.70 0.0170
La FIG. 1 muestra el efecto del sulfato de amonio en la liberación inicial in vitro. Los datos indican que la liberación inicial in vitro se correlaciona con el diámetro del poro de las micropartículas. Las formulaciones hechas con sulfato de amonio mostraron niveles variables de liberación in vitro y una porosidad variable a diferencia de las 10 formulaciones sin sulfato de amonio que exhibieron una porosidad y liberación constantes. Durante la fabricación de micropartículas, la presencia de sulfato de amonio en la fase acuosa puede provocar la desestabilización salina de la sustancia farmacológica durante la preparación de la emulsión interna. Las diferencias en el microentorno de los precipitados pueden contribuir a las diferencias en la porosidad y, por lo tanto, la variación en la liberación inicial. El efecto no se observó en formulaciones preparadas sin sulfato de amonio. Las formulaciones con sacarosa y
15 exendina-4 muestran un nivel de liberación inicial más deseable y constante en comparación con formulaciones que tienen exendina-4, sacarosa y sulfato de amonio.
La FIG. 2 demuestra además el efecto de la porosidad en la liberación in vitro y el impacto que las condiciones del procesamiento, concretamente la relación del aceite de silicona respecto al diclorometano, tiene en la porosidad de las micropartículas formadas. Resumiendo, las formulaciones de micropartículas preparadas utilizando una relación
20 del aceite de silicona respecto al diclorometano de 1:1 (Formulaciones 2-4 y 2-5 de la Tabla 1) tienen una liberación inicial más elevada que las mismas formulaciones preparadas utilizando una relación del aceite de silicona respecto al diclorometano de 1.5:1 (Formulaciones 2, 2-1 y 2-2 de la Tabla 1). La FIG. 2 sugiere que una relación más elevada del aceite de silicona respecto al diclorometano conlleva una porosidad menor lo que conlleva una liberación inicial menor.
Se llevaron a cabo análisis por SEM criogénica tal y como se ha descrito anteriormente con las Formulaciones de los tipos 2, 3 y 5 de la Tabla 1. Las FIGS. 3A-3B son barridos de micrografías para formulaciones seleccionadas de tipo 2 (Formulación 2-2, FIG. 3A) y de tipo 5 (5% de exendina-4, 2% de sacarosa, FIG. 3B). Las FIGS. 4A-D son barridos
13
Claims (1)
-
imagen1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20110180259 EP2409707B8 (en) | 2004-04-15 | 2004-04-15 | Polymer-based sustained release device |
PCT/US2004/011547 WO2005110425A1 (en) | 2004-04-15 | 2004-04-15 | Polymer-based sustained release device |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2536235T3 true ES2536235T3 (es) | 2015-05-21 |
Family
ID=35393985
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11180259.1T Expired - Lifetime ES2536235T3 (es) | 2004-04-15 | 2004-04-15 | Dispositivo polimérico de liberación prolongada |
ES04750134T Expired - Lifetime ES2375802T3 (es) | 2004-04-15 | 2004-04-15 | Dispositivo de liberación sostenida a base de pol�?mero. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES04750134T Expired - Lifetime ES2375802T3 (es) | 2004-04-15 | 2004-04-15 | Dispositivo de liberación sostenida a base de pol�?mero. |
Country Status (25)
Country | Link |
---|---|
US (7) | US8617613B2 (es) |
EP (2) | EP2409707B8 (es) |
JP (1) | JP5030292B2 (es) |
KR (2) | KR101040415B1 (es) |
CN (1) | CN1968700A (es) |
AT (1) | ATE531374T1 (es) |
AU (1) | AU2004319756C1 (es) |
BR (1) | BRPI0418702A (es) |
CA (1) | CA2560981C (es) |
CY (2) | CY2012010I2 (es) |
DE (1) | DE122012000028I1 (es) |
DK (1) | DK1734971T3 (es) |
EA (1) | EA200601904A1 (es) |
ES (2) | ES2536235T3 (es) |
FR (1) | FR12C0029I1 (es) |
HK (2) | HK1099693A1 (es) |
HR (2) | HRP20110831T1 (es) |
IL (1) | IL178589A0 (es) |
LU (1) | LU91989I2 (es) |
MX (1) | MXPA06011924A (es) |
NO (1) | NO20065217L (es) |
PL (2) | PL1734971T3 (es) |
PT (2) | PT1734971E (es) |
SI (1) | SI2409707T1 (es) |
WO (1) | WO2005110425A1 (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
WO2005110425A1 (en) | 2004-04-15 | 2005-11-24 | Alkermes, Inc. | Polymer-based sustained release device |
US20090069226A1 (en) * | 2004-05-28 | 2009-03-12 | Amylin Pharmaceuticals, Inc. | Transmucosal delivery of peptides and proteins |
EP1679065A1 (en) * | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
EP1904525A4 (en) * | 2005-06-30 | 2009-10-21 | Ipsen Pharma | GLP-1 PHARMACEUTICAL COMPOSITIONS |
EP1971362B1 (en) * | 2005-08-19 | 2014-12-03 | Amylin Pharmaceuticals, LLC | Exendin for treating diabetes and reducing body weight |
JP5143131B2 (ja) | 2006-05-30 | 2013-02-13 | インターシア セラピューティクス,インコーポレイティド | 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ |
PL2359808T3 (pl) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotyczne systemy dostawcze i zespoły tłokowe |
EP2131815A4 (en) * | 2007-03-22 | 2012-11-07 | Alkermes Inc | coacervation |
KR100805208B1 (ko) * | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
EP2139458A4 (en) * | 2007-04-19 | 2013-01-23 | Dong A Pharm Co Ltd | COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA |
MX2009011123A (es) * | 2007-04-23 | 2009-11-02 | Intarcia Therapeutics Inc | Formulaciones de suspensiones de peptidos insulinotropicos y sus usos. |
US20080317865A1 (en) * | 2007-06-20 | 2008-12-25 | Alkermes, Inc. | Quench liquids and washing systems for production of microparticles |
US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
US8642062B2 (en) | 2007-10-31 | 2014-02-04 | Abbott Cardiovascular Systems Inc. | Implantable device having a slow dissolving polymer |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
US8916188B2 (en) * | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
WO2009143285A2 (en) | 2008-05-21 | 2009-11-26 | Amylin Pharmaceuticals, Inc. | Exendins to lower cholestrol and triglycerides |
LT2341905T (lt) * | 2008-09-04 | 2020-09-25 | Amylin Pharmaceuticals, Llc | Pailginto atpalaidavimo vaisto formos su nevandeniniais nešikliais |
NZ598686A (en) | 2009-09-28 | 2014-05-30 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
AU2013366691A1 (en) | 2012-12-21 | 2015-07-09 | Sanofi | Exendin-4 derivatives |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
CN103720663B (zh) * | 2014-01-08 | 2016-04-06 | 昆药集团股份有限公司 | 一种促卵泡激素缓释微球及其制备方法 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
CN105769771B (zh) * | 2014-12-25 | 2019-02-01 | 四川科伦药物研究院有限公司 | 一种艾塞那肽缓释微球组合物及其制备方法 |
EP3936143A1 (en) | 2015-05-22 | 2022-01-12 | The Board of Trustees of the Leland Stanford Junior University | Treatment of post-bariatric hypoglycemia with exendin (9-39) |
AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
WO2017152014A1 (en) | 2016-03-04 | 2017-09-08 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
CN109310743A (zh) | 2016-05-16 | 2019-02-05 | 因塔西亚制药公司 | 胰高血糖素受体选择性多肽及其使用方法 |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
WO2018057977A1 (en) | 2016-09-23 | 2018-03-29 | Delpor, Inc. | Stable compositions for incretin mimetic compounds |
US11020484B2 (en) | 2016-11-21 | 2021-06-01 | Eiger Biopharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
EP3372224A1 (en) | 2017-03-07 | 2018-09-12 | Alrise Biosystems GmbH | New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles |
WO2020198798A1 (en) * | 2019-04-02 | 2020-10-08 | Cytomatrix Limited | A composition for the delivery of biologically active agents and uses thereof |
US20230201174A1 (en) | 2020-04-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
US11930804B2 (en) | 2020-05-21 | 2024-03-19 | Florida Power & Light Company | Avian streamer deterrent for electric power line support structures |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL280825A (es) * | 1962-07-11 | |||
BE744162A (fr) * | 1969-01-16 | 1970-06-15 | Fuji Photo Film Co Ltd | Procede d'encapsulage |
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
DE2010115A1 (de) * | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
JPS523342B2 (es) * | 1972-01-26 | 1977-01-27 | ||
GB1413186A (en) * | 1973-06-27 | 1975-11-12 | Toyo Jozo Kk | Process for encapsulation of medicaments |
JPS523653A (en) * | 1975-06-27 | 1977-01-12 | Fuji Photo Film Co Ltd | Process for producing fine polymer particles |
US4384975A (en) * | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
JPS57119318A (en) * | 1981-01-16 | 1982-07-24 | Minolta Camera Co Ltd | Filter having special effect |
US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
US5639639A (en) * | 1983-11-02 | 1997-06-17 | Genzyme Corporation | Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof |
US4923805A (en) * | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
US4840896A (en) | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
IE59361B1 (en) * | 1986-01-24 | 1994-02-09 | Akzo Nv | Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension |
US4737437A (en) * | 1986-03-27 | 1988-04-12 | East Shore Chemical Co. | Light sensitive diazo compound, composition and method of making the composition |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
GB8723846D0 (en) * | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
AU2810189A (en) | 1987-10-30 | 1989-05-23 | Stolle Research & Development Corporation | Low residual solvent microspheres and microencapsulation process |
JP2827287B2 (ja) | 1988-07-05 | 1998-11-25 | 武田薬品工業株式会社 | 水溶性薬物含有徐放型マイクロカプセル |
US5271945A (en) | 1988-07-05 | 1993-12-21 | Takeda Chemical Industries, Ltd. | Sustained release microcapsule for water soluble drug |
IL92344A0 (en) * | 1989-01-04 | 1990-07-26 | Gist Brocades Nv | Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules |
US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
CA2030551C (en) | 1989-05-01 | 1998-08-25 | Wayne Gombotz | Process for producing small particles of biologically active molecules |
DE69024953T3 (de) * | 1989-05-04 | 2005-01-27 | Southern Research Institute, Birmingham | Einkapselungsverfahren |
US5225205A (en) * | 1989-07-28 | 1993-07-06 | Debiopharm S.A. | Pharmaceutical composition in the form of microparticles |
JPH05502465A (ja) * | 1989-08-28 | 1993-04-28 | ファーマスーティカル デリバリー システムズ | 治療薬剤の制御放出のために有用な生体内で分解し得るポリマー |
US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5126147A (en) * | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
US5478564A (en) | 1990-02-22 | 1995-12-26 | Teva Pharmaceutical Industries, Ltd. | Preparation of microparticles for controlled release of water-soluble substances |
IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
CA2102507A1 (en) | 1991-05-07 | 1992-11-08 | Judith P. Kitchell | A controlled, sustained release delivery system for smoking cessation |
HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
US5658593A (en) * | 1992-01-16 | 1997-08-19 | Coletica | Injectable compositions containing collagen microcapsules |
JP3267972B2 (ja) * | 1992-02-28 | 2002-03-25 | コラーゲン コーポレイション | 高濃度均質化コラーゲン組成物 |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US6514533B1 (en) * | 1992-06-11 | 2003-02-04 | Alkermas Controlled Therapeutics, Inc. | Device for the sustained release of aggregation-stabilized, biologically active agent |
ES2077547T3 (es) | 1992-11-17 | 2000-06-16 | Yoshitomi Pharmaceutical | Microesfera de liberacion sostenida que contiene un antipsicotico y procedimiento de produccion. |
ATE195652T1 (de) * | 1992-12-02 | 2000-09-15 | Alkermes Inc | Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung |
ATE197550T1 (de) * | 1993-02-23 | 2000-12-15 | Genentech Inc | Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff |
US5981719A (en) * | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
TW360548B (en) * | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
HU219487B (hu) * | 1993-11-19 | 2001-04-28 | Janssen Pharmaceutica Nv. | Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk |
US5650173A (en) * | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
DE69429820T3 (de) * | 1993-11-19 | 2013-02-28 | Alkermes Controlled Therapeutics, Inc. | Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel |
JPH07196479A (ja) | 1994-01-04 | 1995-08-01 | Unitika Ltd | マイクロカプセルの製造法 |
US5922253A (en) | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
US6369116B1 (en) * | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US5942253A (en) * | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
SE505146C2 (sv) * | 1995-10-19 | 1997-06-30 | Biogram Ab | Partiklar för fördröjd frisättning |
DE69624087T2 (de) * | 1996-01-31 | 2003-06-05 | Sumitomo Bakelite Co | Verfahren zur Herstellung von in Epoxyharz eingekapselter Halbleitervorrichtung |
CZ297338B6 (cs) * | 1996-03-01 | 2006-11-15 | Novo Nordisk A/S | Peptid potlacující chut k jídlu, farmaceutický prostredek jej obsahující a jeho pouzití |
EP0889722B1 (en) * | 1996-03-28 | 2002-11-20 | Takeda Chemical Industries, Ltd. | Sustained-release preparation and its production |
US5792477A (en) * | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
DE69724451T2 (de) * | 1996-12-06 | 2004-03-18 | Amgen Inc., Thousand Oaks | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen |
US5945126A (en) * | 1997-02-13 | 1999-08-31 | Oakwood Laboratories L.L.C. | Continuous microsphere process |
AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
GB9718986D0 (en) | 1997-09-09 | 1997-11-12 | Danbiosyst Uk | Controlled release microsphere delivery system |
US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
CA2335460A1 (en) * | 1998-06-18 | 1999-12-23 | Johns Hopkins University School Of Medicine | Polymers for delivery of nucleic acids |
US6194006B1 (en) * | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
US20030087820A1 (en) * | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
US6268630B1 (en) * | 1999-03-16 | 2001-07-31 | Sandia Corporation | Silicon-on-insulator field effect transistor with improved body ties for rad-hard applications |
ES2261195T3 (es) | 1999-04-05 | 2006-11-16 | Mannkind Corporation | Metodo de formacion de particulas finas. |
US6291013B1 (en) | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
US6506724B1 (en) * | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
SE9903236D0 (sv) | 1999-09-10 | 1999-09-10 | Astra Ab | Method to obtain microparticles |
US6284283B1 (en) * | 1999-10-21 | 2001-09-04 | Alkermes Controlled Therapeutics, Inc. | Method of producing sub-micron particles of biologically active agents and uses thereof |
US6465425B1 (en) * | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US6479065B2 (en) * | 2000-08-10 | 2002-11-12 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
US6824822B2 (en) * | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
US6558702B2 (en) * | 2001-04-13 | 2003-05-06 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
US20030003074A1 (en) * | 2001-06-14 | 2003-01-02 | Macromed, Inc. | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
JP4665141B2 (ja) * | 2001-06-29 | 2011-04-06 | 富士通セミコンダクター株式会社 | 半導体装置とその製造方法 |
WO2003066585A2 (en) | 2002-02-08 | 2003-08-14 | Alkermes Controlled Therapeutics, Inc. | Polymer-based compositions for sustained release |
WO2004035762A2 (en) | 2002-10-17 | 2004-04-29 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulation and sustained release of biologically active polypeptides |
WO2004034975A2 (en) * | 2002-10-17 | 2004-04-29 | Alkermes Controlled Therapeutics, Inc. | Sustained release profile modification |
US6887613B2 (en) * | 2002-12-04 | 2005-05-03 | General Motors Corporation | Corrosion resistant PEM fuel cell |
US20040247672A1 (en) | 2003-05-16 | 2004-12-09 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
US6968927B2 (en) * | 2003-10-10 | 2005-11-29 | Brian Scura | Bicycle force balancing mechanism with a brake arm actuation assembly and a pivot member for dual main brake cable segments |
WO2005110425A1 (en) * | 2004-04-15 | 2005-11-24 | Alkermes, Inc. | Polymer-based sustained release device |
US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
US20060110423A1 (en) * | 2004-04-15 | 2006-05-25 | Wright Steven G | Polymer-based sustained release device |
EP2131815A4 (en) * | 2007-03-22 | 2012-11-07 | Alkermes Inc | coacervation |
-
2004
- 2004-04-15 WO PCT/US2004/011547 patent/WO2005110425A1/en active Application Filing
- 2004-04-15 JP JP2007508312A patent/JP5030292B2/ja not_active Expired - Lifetime
- 2004-04-15 AU AU2004319756A patent/AU2004319756C1/en active Active
- 2004-04-15 PL PL04750134T patent/PL1734971T3/pl unknown
- 2004-04-15 SI SI200432227T patent/SI2409707T1/sl unknown
- 2004-04-15 PT PT04750134T patent/PT1734971E/pt unknown
- 2004-04-15 BR BRPI0418702-4A patent/BRPI0418702A/pt not_active IP Right Cessation
- 2004-04-15 DK DK04750134.1T patent/DK1734971T3/da active
- 2004-04-15 AT AT04750134T patent/ATE531374T1/de active
- 2004-04-15 EA EA200601904A patent/EA200601904A1/ru unknown
- 2004-04-15 ES ES11180259.1T patent/ES2536235T3/es not_active Expired - Lifetime
- 2004-04-15 ES ES04750134T patent/ES2375802T3/es not_active Expired - Lifetime
- 2004-04-15 KR KR1020067023967A patent/KR101040415B1/ko active IP Right Grant
- 2004-04-15 PT PT111802591T patent/PT2409707E/pt unknown
- 2004-04-15 CA CA2560981A patent/CA2560981C/en not_active Expired - Lifetime
- 2004-04-15 EP EP20110180259 patent/EP2409707B8/en not_active Expired - Lifetime
- 2004-04-15 CN CNA2004800433214A patent/CN1968700A/zh active Pending
- 2004-04-15 PL PL11180259T patent/PL2409707T3/pl unknown
- 2004-04-15 EP EP04750134A patent/EP1734971B8/en not_active Expired - Lifetime
- 2004-04-15 MX MXPA06011924A patent/MXPA06011924A/es active IP Right Grant
- 2004-04-15 KR KR1020107026352A patent/KR20100129799A/ko not_active Application Discontinuation
- 2004-04-15 US US10/592,769 patent/US8617613B2/en active Active
-
2006
- 2006-09-14 US US11/521,091 patent/US7563871B2/en not_active Expired - Lifetime
- 2006-10-15 IL IL178589A patent/IL178589A0/en unknown
- 2006-11-14 NO NO20065217A patent/NO20065217L/no not_active Application Discontinuation
-
2007
- 2007-06-22 HK HK07106714.5A patent/HK1099693A1/xx unknown
- 2007-07-20 US US11/878,160 patent/US20080119569A1/en not_active Abandoned
- 2007-07-20 US US11/878,159 patent/US20080125351A1/en not_active Abandoned
-
2009
- 2009-06-12 US US12/483,871 patent/US20090247463A1/en not_active Abandoned
-
2011
- 2011-11-11 HR HR20110831T patent/HRP20110831T1/hr unknown
-
2012
- 2012-04-26 CY CY2012010C patent/CY2012010I2/el unknown
- 2012-04-27 FR FR12C0029C patent/FR12C0029I1/fr active Active
- 2012-04-30 LU LU91989C patent/LU91989I2/fr unknown
- 2012-04-30 DE DE201212000028 patent/DE122012000028I1/de active Pending
- 2012-07-24 HK HK12107269.5A patent/HK1166606A1/xx unknown
-
2013
- 2013-01-16 US US13/743,117 patent/US9238076B2/en active Active
- 2013-11-22 US US14/087,132 patent/US8877252B2/en not_active Expired - Lifetime
-
2015
- 2015-03-10 HR HRP20150272TT patent/HRP20150272T1/hr unknown
- 2015-04-23 CY CY20151100373T patent/CY1116337T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2536235T3 (es) | Dispositivo polimérico de liberación prolongada | |
PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
AR048500A1 (es) | Solidos supersaturados estabilizados de drogas lipofilicas | |
RU2004137118A (ru) | Фармацевтическая композиция для контролируемого высвобождения активных веществ и способ ее изготовления | |
RU2009116933A (ru) | Новые депо-композиции для инъекций и способ изготовления указанных композиций | |
Soltani et al. | Design of eudragit RL nanoparticles by nanoemulsion method as carriers for ophthalmic drug delivery of ketotifen fumarate | |
BR0312007A (pt) | Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas | |
EP2127642A3 (en) | Microemulsions as solid dosage forms for oral administration | |
Dixit et al. | Lyophilization monophase solution technique for improvement of the solubility and dissolution of piroxicam | |
RU2333745C2 (ru) | Композиции с контролируемым высвобождением | |
ES2573539T3 (es) | Inhibidor de la cristalización y su uso en cápsulas de gelatina | |
CR7936A (es) | Formulaciones parenterales de un peptido para el tratamiento de lupus sitemico eritematoso | |
KR20140056280A (ko) | 비마토프로스트 및 브리모니딘의 고정된 용량 조합 | |
ES2895764T3 (es) | Dispositivo de microagujas | |
RU2006133543A (ru) | Фармацевтическая композиция для орального применения и способ ее приготовления | |
US20090054531A1 (en) | Eye drop preparation comprising xanthan gum and terpenoid | |
TW200423968A (en) | Formulation and dosage form providing increased bioavailability of hydrophobic drugs | |
Khanfar et al. | Preparation of sustained-release dosage form of Venlafaxine HCl using liquisolid technique | |
JP2007511519A5 (es) | ||
CA2737463C (en) | Freeze-dried powder preparation of tetrodotoxin and the producing method thereof | |
Gaber et al. | Synthesized nano particles of glimepiride via spray freezing into cryogenic liquid: characterization, antidiabetic activity, and bioavailability | |
US11660344B2 (en) | Transdermal colloidal solution agent | |
CN1942191A (zh) | 含有米氮平的盐的药物组合物 | |
JP2010508306A5 (es) | ||
Shin et al. | Application of TPX polymer membranes for the controlled release of triprolidine |